Particle.news
Download on the App Store
7 ARTICLES
·
3w ago

Eli Lilly's Lepodisiran Achieves 94% Reduction in Genetic Cholesterol in Phase 2 Trial

The siRNA-based drug shows promise as the first potential treatment for lipoprotein(a), a major cardiovascular risk factor, with Phase 3 trials now underway.

Image
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.
Image
Image

Overview

  • Phase 2 trial results presented at the American College of Cardiology meeting reveal lepodisiran reduced lipoprotein(a) (Lp(a)) levels by up to 94% after two doses over one year.
  • The trial, involving 320 participants, confirmed the drug's safety with no serious adverse events reported.
  • Lepodisiran works by targeting messenger RNA to inhibit the production of apolipoprotein(a), a key component of Lp(a).
  • High levels of Lp(a), a genetic risk factor for cardiovascular disease, affect 1.4 billion people globally, with no currently approved treatments.
  • Phase 3 trials are now underway to determine if lowering Lp(a) translates to reduced cardiovascular events such as heart attacks and strokes, with patient enrollment expected to conclude this year.